J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa_老虎社区_美港股上老虎

J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa

Bloomberg2021-11-30

Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

katzkie
·2021-11-30
Ok
回复
2
举报
RetroFreedom
·2021-11-30
J&J Long! Expect more things after reorganisation.
回复
2
举报
scenichu
·2021-11-30
[Smile]
回复
5
举报
SimplicityB
·2021-11-30
👍🏻
回复
4
举报
BBBBBBBBBB
·2021-11-30
Ok
回复
2
举报
Jeromelim
·2021-11-30
ok
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1151752046?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-30 21:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151752046","market":"us","top_or_hot":-1,"title":"J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa","media":"Bloomberg","content":"<div>\n<p>Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp\">网页链接</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp","article_id":"1151752046","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151752046","pubTimestamp":1638280743,"columns":[],"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensi","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"强生公司与阿斯彭公司达成协议，为非洲生产自有品牌疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.\nThe agreement, confirmed by Aspen in a statement Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.\nAspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&J shot and plans to increase that over time to more than 700 million by January 2023.\nShares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":609205428,"gmtCreate":1638284134313,"gmtModify":1638284134313,"author":{"id":"4100839201174830","authorId":"4100839201174830","name":"katzkie","avatar":"https://static.tigerbbs.com/26d7196486e37e1d51f3e1068c72ef51","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4100839201174830","authorIdStr":"4100839201174830"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609205428","repostId":1151752046,"repostType":4,"repost":{"id":"1151752046","kind":"news","pubTimestamp":1638280743,"share":"https://www.laohu8.com/m/news/1151752046?lang=&edition=full","pubTime":"2021-11-30 21:59","market":"us","language":"en","title":"J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=1151752046","media":"Bloomberg","summary":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensi","content":"<p>Johnson &amp; Johnson&nbsp;and&nbsp;Aspen Pharmacare Holdings Ltd.&nbsp;have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.</p>\n<p>The agreement, confirmed by Aspen in&nbsp;a statement&nbsp;Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.</p>\n<p>Aspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&amp;J shot and plans to increase that over time to more than 700 million by January 2023.</p>\n<p>Shares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151752046","content_text":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.\nThe agreement, confirmed by Aspen in a statement Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.\nAspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&J shot and plans to increase that over time to more than 700 million by January 2023.\nShares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609643990,"gmtCreate":1638282764353,"gmtModify":1638282764353,"author":{"id":"3577319149726586","authorId":"3577319149726586","name":"RetroFreedom","avatar":"https://static.tigerbbs.com/6b00161f79e3ca894c5687f5f4139635","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3577319149726586","authorIdStr":"3577319149726586"},"htmlText":"J&amp;J Long! Expect more things after reorganisation.","listText":"J&amp;J Long! Expect more things after reorganisation.","text":"J&J Long! Expect more things after reorganisation.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609643990","repostId":1151752046,"repostType":4,"repost":{"id":"1151752046","kind":"news","pubTimestamp":1638280743,"share":"https://www.laohu8.com/m/news/1151752046?lang=&edition=full","pubTime":"2021-11-30 21:59","market":"us","language":"en","title":"J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=1151752046","media":"Bloomberg","summary":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensi","content":"<p>Johnson &amp; Johnson&nbsp;and&nbsp;Aspen Pharmacare Holdings Ltd.&nbsp;have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.</p>\n<p>The agreement, confirmed by Aspen in&nbsp;a statement&nbsp;Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.</p>\n<p>Aspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&amp;J shot and plans to increase that over time to more than 700 million by January 2023.</p>\n<p>Shares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151752046","content_text":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.\nThe agreement, confirmed by Aspen in a statement Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.\nAspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&J shot and plans to increase that over time to more than 700 million by January 2023.\nShares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609659177,"gmtCreate":1638281894796,"gmtModify":1638281895108,"author":{"id":"3554951292305587","authorId":"3554951292305587","name":"scenichu","avatar":"https://static.tigerbbs.com/e2d5eb7de52de2d76f08c9564d26fe90","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3554951292305587","authorIdStr":"3554951292305587"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609659177","repostId":1151752046,"repostType":4,"repost":{"id":"1151752046","kind":"news","pubTimestamp":1638280743,"share":"https://www.laohu8.com/m/news/1151752046?lang=&edition=full","pubTime":"2021-11-30 21:59","market":"us","language":"en","title":"J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=1151752046","media":"Bloomberg","summary":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensi","content":"<p>Johnson &amp; Johnson&nbsp;and&nbsp;Aspen Pharmacare Holdings Ltd.&nbsp;have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.</p>\n<p>The agreement, confirmed by Aspen in&nbsp;a statement&nbsp;Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.</p>\n<p>Aspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&amp;J shot and plans to increase that over time to more than 700 million by January 2023.</p>\n<p>Shares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151752046","content_text":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.\nThe agreement, confirmed by Aspen in a statement Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.\nAspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&J shot and plans to increase that over time to more than 700 million by January 2023.\nShares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609626024,"gmtCreate":1638281278786,"gmtModify":1638281278786,"author":{"id":"4100955241207960","authorId":"4100955241207960","name":"SimplicityB","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4100955241207960","authorIdStr":"4100955241207960"},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609626024","repostId":1151752046,"repostType":4,"repost":{"id":"1151752046","kind":"news","pubTimestamp":1638280743,"share":"https://www.laohu8.com/m/news/1151752046?lang=&edition=full","pubTime":"2021-11-30 21:59","market":"us","language":"en","title":"J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=1151752046","media":"Bloomberg","summary":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensi","content":"<p>Johnson &amp; Johnson&nbsp;and&nbsp;Aspen Pharmacare Holdings Ltd.&nbsp;have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.</p>\n<p>The agreement, confirmed by Aspen in&nbsp;a statement&nbsp;Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.</p>\n<p>Aspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&amp;J shot and plans to increase that over time to more than 700 million by January 2023.</p>\n<p>Shares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151752046","content_text":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.\nThe agreement, confirmed by Aspen in a statement Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.\nAspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&J shot and plans to increase that over time to more than 700 million by January 2023.\nShares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609623754,"gmtCreate":1638281189297,"gmtModify":1638281189518,"author":{"id":"3581562365927542","authorId":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581562365927542","authorIdStr":"3581562365927542"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609623754","repostId":1151752046,"repostType":4,"repost":{"id":"1151752046","kind":"news","pubTimestamp":1638280743,"share":"https://www.laohu8.com/m/news/1151752046?lang=&edition=full","pubTime":"2021-11-30 21:59","market":"us","language":"en","title":"J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=1151752046","media":"Bloomberg","summary":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensi","content":"<p>Johnson &amp; Johnson&nbsp;and&nbsp;Aspen Pharmacare Holdings Ltd.&nbsp;have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.</p>\n<p>The agreement, confirmed by Aspen in&nbsp;a statement&nbsp;Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.</p>\n<p>Aspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&amp;J shot and plans to increase that over time to more than 700 million by January 2023.</p>\n<p>Shares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151752046","content_text":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.\nThe agreement, confirmed by Aspen in a statement Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.\nAspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&J shot and plans to increase that over time to more than 700 million by January 2023.\nShares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609629167,"gmtCreate":1638281103518,"gmtModify":1638281103641,"author":{"id":"4087798944081960","authorId":"4087798944081960","name":"Jeromelim","avatar":"https://static.tigerbbs.com/45cd82e500d76165963f39f22aa6230e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087798944081960","authorIdStr":"4087798944081960"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609629167","repostId":1151752046,"repostType":4,"repost":{"id":"1151752046","kind":"news","pubTimestamp":1638280743,"share":"https://www.laohu8.com/m/news/1151752046?lang=&edition=full","pubTime":"2021-11-30 21:59","market":"us","language":"en","title":"J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=1151752046","media":"Bloomberg","summary":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensi","content":"<p>Johnson &amp; Johnson&nbsp;and&nbsp;Aspen Pharmacare Holdings Ltd.&nbsp;have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.</p>\n<p>The agreement, confirmed by Aspen in&nbsp;a statement&nbsp;Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.</p>\n<p>Aspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&amp;J shot and plans to increase that over time to more than 700 million by January 2023.</p>\n<p>Shares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Nears Deal for Aspen to Make Own-Brand Vaccine for Africa\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/j-j-nears-deal-for-aspen-to-make-own-brand-vaccine-for-africa?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151752046","content_text":"Johnson & Johnson and Aspen Pharmacare Holdings Ltd. have agreed on terms that may lead to a licensing deal allowing the South African drug company to make its own-branded Covid-19 vaccine and decide on the recipients of the doses it produces.\nThe agreement, confirmed by Aspen in a statement Tuesday, would extend an existing deal for it to package and fill vials of the U.S. company’s shots at a plant in South Africa. The development comes as the emergence of the omicron variant again highlights the need for better global vaccine equality, with African nations trailing more developed countries on coronavirus inoculations.\nAspen, Africa’s largest drugmaker, has capacity to manufacture as many as 300 million doses of the J&J shot and plans to increase that over time to more than 700 million by January 2023.\nShares in the Durban, South Africa-based company rose 5.9% as of 2:15 p.m. in Johannesburg, bringing the gain this year to more than 89%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":59,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}